|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Here, we show that TC11 does not induce degradation of CRBN's substrates, IKZF1/3 and CK1α, and induces apoptosis of CRBN-silenced MM; this effect was independent of the cereblon (CRBN) pathway, which is involved in the mechanism of action of IMiDs used for the treatment of MM.
|
31653349 |
2020 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The immunomodulatory drugs (IMiDs) thalidomide and its analogs, lenalidomide and pomalidomide, all FDA approved drugs for the treatment of multiple myeloma, induce ubiquitination and degradation of the lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase for proteasomal degradation.
|
31157769 |
2019 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We also demonstrated that treatment with a pan-PIM kinase inhibitor resulted in increased expression of cereblon, and that knockdown of cereblon via a shRNA lentivirus abolished the effects of PIM kinase inhibition on the degradation of IKZF1 and IKZF3 and myeloma cell apoptosis, demonstrating a central role of cereblon in pan-PIM kinase inhibitor-mediated down-regulation of IKZF1 and IKZF3 and myeloma cell killing.
|
30312729 |
2019 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Immunomodulatory drugs (IMiDs) including lenalidomide and pomalidomide bind cereblon (CRBN) and activate the CRL4<sup>CRBN</sup> ubiquitin ligase to trigger proteasomal degradation of the essential transcription factors IKZF1 and IKZF3 and multiple myeloma (MM) cytotoxicity.
|
30026574 |
2019 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation.
|
30760870 |
2019 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
<b>Experimental design</b>: We analysed the IKZF1/3 expression levels in T-cells from 45 MM stage I (MMI) and 50 newly diagnosed MM stage III (MMIII) patients, according to Durie-Salmon staging system, by flow cytometry to examine their prognostic and predictive value.
|
30288348 |
2018 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Our results suggest that baicalein suppresses the growth and promotes apoptosis of myeloma U266 cells through downregulating IKZF1 and IKZF3.
|
29729093 |
2018 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all approved for the treatment of multiple myeloma, induce targeted ubiquitination and degradation of Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase.
|
30118587 |
2018 |
|
Multiple Myeloma
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Host genetic susceptibility to Clostridium difficile infections in patients undergoing autologous stem cell transplantation: a genome-wide association study.
|
29594489 |
2018 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
For example, UBE2G1 inactivation significantly attenuated the degradation of myeloma survival factors IKZF1 and IKZF3 induced by lenalidomide and pomalidomide, hence conferring drug resistance.
|
30234487 |
2018 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Lenalidomide (LEN) acts directly on multiple myeloma (MM) cells by inducing cereblon-mediated degradation of interferon regulatory factor 4, Ikaros (IKZF)1 and IKZF3, transcription factors that are essential for MM cell survival.
|
28643330 |
2017 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest a prognostic role of IKZF1, IKZF3 and BSG expression levels in lenalidomide-treated multiple myeloma.
|
28017969 |
2017 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
|
28052520 |
2017 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
|
26269456 |
2015 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
IKZF1 and IKZF3 are essential transcription factors in multiple myeloma.
|
24292625 |
2014 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Analysis of myeloma cell lines revealed that loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect, suggesting that the antitumor and teratogenic activities of thalidomide-like drugs are dissociable.
|
24292623 |
2014 |